2022 Southern Medical Research Conference



advanced heart failure clinic :: Article Creator

High Point Woman Who Beat Cancer Put On The Heart Transplant List

© Provided by WAVY Norfolk

HIGH POINT, N.C. (WGHP) — A High Point woman has made it onto the heart transplant list after living with a heart pump for nearly seven years.

Sabrey Smith's journey began in 2013 when she learned she had a blot clot and soon after was diagnosed with congestive heart failure.

"I couldn't even walk two steps. Out of breath. Gasping for air…I couldn't even go up a staircase," Sabrey Smith said.

She was living in Houston, Texas, at the time, working two jobs and mourning the death of her son. Her doctors advised her to move closer to her family.

After moving to High Point, Sabrey underwent open heart surgery in 2016 at Cone Health Heart and Vascular Center to receive a heart pump.

"The surgery takes about four hours, and they're in the hospital 10 to 14 days…after surgery because they're so weak to begin with," said Dr. Peter Van Trigt, a cardiothoracic surgeon.

A left ventricle assist device, also known as an LVAD, keeps her heart pumping.

Sabrey and her doctors say it was a lifesaving surgery that helped her maintain her active lifestyle. She provides transportation to the elderly for doctor's appointments, grocery pick up and hosts community events.

"Most…patients that are receiving a heart pump. This is to save their life. They're at the end of life," Trigt said.

"If I hadn't have gotten this LVAD when I did, I think I'd have been long gone," Sabrey said.

This month marks the 10th anniversary of the heart pump program at Cone Health. During the past decade, doctors at the hospital have installed 120 of them.

"About 10 to 15% of those patients we hope to get on to get onto the heart transplant list and actually get them transplanted. So while you may get five to 10 years from a heart pump, you could get another 10 to 20 or 25 years with a transplant," said Dr. Dan Bensimhon, medical director of Advanced Heart Failure Clinic & Mechanical Support Program at Moses Cone Hospital.

Two years after getting her heart pump, Sabrey looked to see if she qualified for a heart transplant, facing another obstacle.

"When I went to see if I was a candidate for a heart transplant…they found cancer. Breast cancer," Sabrey said.

A few years later after ringing the bell cancer free, she encountered another hurdle.

"The second time I went, which was last year, I needed to drop like 20 pounds because my A1c was too high," Sabrey said.

A few weeks ago on April 25, she got the call she was on the heart transplant list.

"She was given three major things, and she really took that serious and realized, 'hey…I could get 10 to 20 more years.' And she worked hard and did all of those things," said Sara Herbert, VAD coordinator.

Now on the list, they could get the call any day for the heart. Sabrey said she is packed and ready to go to Duke University Hospital when that day comes.

Sabrey's family has launched a GoFundMe to help raise money that will cover expenses during her travels to Duke University Hospital for heart transplant surgery.

Copyright 2022 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

For the latest news, weather, sports, and streaming video, head to WAVY.Com.


Advanced Heart Failure And Transplant Cardiology Fellowship Program

Thank you for your interest in the UAB advanced heart failure and transplant cardiology fellowship program. We are very proud of our training program as it provides the foundation of excellence for our clinical programs. This one-year fellowship is offered to those who have completed a general cardiology fellowship (PGY7 level or greater) and are seeking advanced training in the subspecialty of advanced heart failure, cardiac transplantation, mechanical circulatory support and pulmonary vascular disease.

Program Highlights

  • Robust inpatient & outpatient experience in advanced heart failure, transplant cardiology, mechanical circulatory support & pulmonary vascular disease

  • Dedicated 20 bed Heart Transplant ICU (HTICU)

  • Regional & National leader in heart transplant & mechanical circulatory support (MCS)

  • Management of cardiogenic shock with temporary MCS

  • Extensive exposure in dual organ transplant including Heart/Lung & Heart/Kidney combined transplant

  • Robust pulmonary hypertension experience with one of the largest PH clinics in the southeast

  • Dedicated ECMO program

  • Participation in leading edge research & clinical trials

  • Tertiary/Quaternary referral center, UAB is the 3rd largest public teaching hospital in the US

  • UAB named "Best Large Employer" by Forbes magazine in 2021

    • Exceptional Experience:

    The UAB advanced heart failure fellowship program offers comprehensive training in advanced heart failure, MCS and transplant with the goal of training the emerging leaders in the field. Our fellows will rotate between the inpatient and outpatient settings. The outpatient time is spent in our busy subspecialty clinic (the Kirklin Clinic), including CHF, PH, VAD and transplant clinics as well as in the biopsy suite doing procedures.

    The hub of our inpatient experience is centered in our heart transplant ICU (HTICU) led by our dedicated and supportive faculty. Here we manage the cutting edge heart transplant, VAD and PH clinical programs drawing referrals from all over the region. We use a unique multi-disciplinary approach to manage the most critically ill patients with cardiovascular disease. We have robust heart transplant and VAD programs with patient outcomes that are among the best in the nation. We partner with CV surgery and interventional/ structural cardiologists in the treatment of cardiogenic shock with temporary MCS including ECMO, Impella, TandemHeart. Our HF fellows actively participate in the evaluation and management of patients requiring durable VADs/MCS and heart transplant.

    We also offer exposure to unique clinical programs including Cardio-Obstetrics, Cardio-Oncology and Amyloid/infiltrative cardiomyopathies. Our HF cardiologists participate as members of the multidisciplinary valve team managing patients with complex valvular disease. Our HF fellows also have dedicated educational experience in immunology and pathology.

    Dedicated Program Faculty:

    Program Director:Andrew Lenneman, M.D.

    Assistant Program Director:Joanna Joly, M.D.

    Teaching Faculty:Jose Tallaj, M.D.Ayman Haj Assad, M.D.Charles Hoopes, M.D.

    How to Apply:

    Apply to Fellowship


    Oklahoma Heart Institute Opens New Advanced Heart Failure Center

    ERROR: The request could not be satisfied

    Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.

    Generated by cloudfront (CloudFront) Request ID: 6dZCUGBX4cWrANA0Lq_832Qa9uuUi95fRwcC0TtyC0qJzCGxyO3zKA==



    Comments

    Post a Comment

    Popular posts from this blog

    Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

    Image
    Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
    Read more

    Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

    Image
    Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
    Read more

    Analysis: Large pharma companies do little new drug innovation - STAT

    Image
    Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
    Read more